apl. Prof. Dr. Lucie Heinzerling

Medizinische Fakultät Department of Dermatology

The neurotrophin Neuritin1 (cpg15) is involved in melanoma migration, attachment independent growth, and vascular mimicry (2017) Boßerhoff AK, Schneider N, Ellmann L, Heinzerling L, Kuphal S Journal article Predicting the response to anti-PD1 therapy in metastatic melanoma (2016) Heinzerling L, Kirchberger MC, Walter L, Schuler G Journal article, Letter Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) Hassel J, Forschner A, Bluhm L, Heinzerling L, Zimmer L, Utikal J, Kaehler K, et al. Conference contribution Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, et al. Journal article Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy (2016) Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, et al. Journal article Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial (2016) Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hoelzle E, et al. Journal article Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy (2016) Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, et al. Journal article Preferences of German melanoma patients for interferon (IFN) ?-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy (2016) Kaehler KC, Blome C, Forschner A, Gutzmer R, Haalck T, Heinzerling L, Kornek T, et al. Journal article Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma (2016) Kaehler KC, Hassel JC, Heinzerling L, Loquai C, Moessner R, Ugurel S, Zimmer L, Gutzmer R Journal article Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma (2016) Kirchberger MC, Hauschild A, Schuler G, Heinzerling L Journal article